OLIGOMA Trial: SBRT Extends PFS in Oligometastatic Breast Cancer - OncoDaily

OLIGOMA trial showed SBRT improved progression-free survival in oligometastatic breast cancer, supporting metastasis-directed therapy.

OLIGOMA Trial: SBRT Extends PFS in Oligometastatic Breast Cancer The OLIGOMA trial presented at ESTRO 2026 brings new attention to one of the most debated questions in metastatic breast cancer : can treating limited metastatic sites with stereotactic body radiotherapy improve outcomes beyond local tumor control? In this small randomized controlled trial, patients with oligometastatic breast cancer who received metastasis-directed stereotactic body radiotherapy (SBRT) in addition to standard systemic therapy had a substantially longer progression-free survival compared with patients treated wit

related reading

• Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA) - PubMedpubmed.ncbi.nlm.nih.gov
• Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review - PMCpmc.ncbi.nlm.nih.gov
• Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
• Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients | npj Breast Cancernature.com
• The blood cancer that became solvableworksinprogress.news
• A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study | Communications Medicinenature.com
• Progression-free survival - Wikipediaen.wikipedia.org
• Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
• Has pancreatic cancer met its match?worksinprogress.co
• Notionnotion.so
• Diagnosis and surgical treatment of solid pseudopapillary neoplasm of the pancreas: analysis of 24 cases - PMCncbi.nlm.nih.gov
• Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC) - PMCncbi.nlm.nih.gov